Biomarkers

Roadblocks to the use of blood-based biomarkers in clinical care

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

The Phase III LUCIDITY trial: a tau aggregation inhibitor in patients with Alzheimer’s disease

Plasma p-tau181 to identify Alzheimer’s disease-related co-pathology in DLB

Racial and ethnic minorities more likely to be excluded from trials based on biomarker prescreening

Ultra-high field 7T MRI for diagnosis of early Alzheimer’s Disease

Retinal microglia and tau biomarkers in Alzheimer’s disease

Plasma tau217 occupancy as accurate as validated CSF tests

DROP-AD: detecting Alzheimer’s disease biomarkers in a single blood spot

A novel cognitive assessment based on augmented reality and machine learning

Digital biomarkers to revolutionize clinical trial conduction in Alzheimer’s disease

Phase II study of NE3107 in degenerative dementias

Blood-based biomarkers for AD diagnosis

Random forests in large-scale omics studies

Detecting retinal Aβ: a promising path for non-invasive Alzheimer’s disease diagnosis

Prospects for Alzheimer’s disease monitoring and treatment in 2023